​
​

Royalty Pharma (RPRX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Royalty Pharma Revenue Highlights

Latest Revenue (Y)

$2.35B

Latest Revenue (Q)

$564.69M

Main Segment (Y)

Financial Royalty Assets

Royalty Pharma Revenue by Period

Royalty Pharma Revenue by Year

DateRevenueChange
2023-12-31$2.35B5.24%
2022-12-31$2.24B-2.28%
2021-12-31$2.29B7.89%
2020-12-31$2.12B16.96%
2019-12-31$1.81B1.08%
2018-12-31$1.79B12.33%
2017-12-31$1.60B-

Royalty Pharma generated $2.35B in revenue during NA 2023, up 5.24% compared to the previous quarter, and up 131.18% compared to the same period a year ago.

Royalty Pharma Revenue by Quarter

DateRevenueChange
2024-09-30$564.69M5.10%
2024-06-30$537.27M-5.41%
2024-03-31$567.98M-4.70%
2023-12-31$596.00M11.13%
2023-09-30$536.31M-0.35%
2023-06-30$538.20M-21.31%
2023-03-31$683.97M20.90%
2022-12-31$565.75M-1.35%
2022-09-30$573.46M7.00%
2022-06-30$535.96M-4.64%
2022-03-31$562.05M-2.37%
2021-12-31$575.70M-1.72%
2021-09-30$585.77M5.55%
2021-06-30$554.96M-3.15%
2021-03-31$573.03M0.35%
2020-12-31$571.00M5.94%
2020-09-30$539.00M5.49%
2020-06-30$510.93M2.01%
2020-03-31$500.88M9.49%
2019-12-31$457.49M-1.46%
2019-09-30$464.28M1.46%
2019-06-30$457.61M5.23%
2019-03-31$434.88M-

Royalty Pharma generated $564.69M in revenue during Q3 2024, up 5.10% compared to the previous quarter, and up 104.92% compared to the same period a year ago.

Royalty Pharma Revenue Breakdown

Royalty Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20
Intangible Royalty Assets$835.00K$37.48M$171.25M$143.38M
Financial Royalty Assets$2.20B$2.13B$2.07B$1.96B
Royalty Income, Other$155.97M$74.64M$53.13M$19.00M

Royalty Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 23: Financial Royalty Assets (93.34%), Royalty Income, Other (6.62%), and Intangible Royalty Assets (0.04%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Financial Royalty Assets$533.17M$541.55M$523.07M$508.66M$501.35M$664.69M$546.54M$551.68M$515.35M$511.52M$526.21M$505.83M$503.41M$529.63M$524.44M$498.51M$474.18M
Royalty Income, Other$31.52M$26.43M$72.77M$27.40M$36.66M$19.14M$18.92M$20.71M$18.07M$16.94M$17.83M$16.54M$11.42M$7.34M$7.30M$5.33M$3.31M
Intangible Royalty Assets--$238.00K$252.00K$202.00K$143.00K$288.00K$1.07M$2.54M$33.59M$31.65M$63.41M$40.13M$36.06M$40.40M$34.55M$33.45M

Royalty Pharma's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Financial Royalty Assets (94.42%), and Royalty Income, Other (5.58%).

Royalty Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BGNEBeiGene$2.46B$929.17M
RPRXRoyalty Pharma$2.35B$564.69M
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
APLSApellis Pharmaceuticals$366.28M$176.57M
ASNDAscendis Pharma$266.72M$95.89M
DNAGinkgo Bioworks$251.46M$89.05M
BPMCBlueprint Medicines$249.38M$128.18M
ADPTAdaptive Bio$170.28M$46.44M
CVACCureVac$52.70M$12.37M
VECTVectivBio$27.34M$676.00K
IKNAIkena Oncology$9.16M-
IOVAIovance Biotherapeutics$1.19M$58.55M
KRTXKaruna Therapeutics$654.00K-
KNTEKinnate Biopharma--
DAWNDay One Biopharmaceuticals-$20.07M
PRMEPrime Medicine-$39.31M
MDGLMadrigal Pharmaceuticals-$62.17M
OCEAOcean Biomedical--
AKROAkero Therapeutics--
RPHMReneo Pharmaceuticals--

RPRX Revenue FAQ

What is Royalty Pharma’s yearly revenue?

Royalty Pharma's yearly revenue for 2023 was $2.35B, representing an increase of 5.24% compared to 2022. The company's yearly revenue for 2022 was $2.24B, representing a decrease of -2.28% compared to 2021. RPRX's yearly revenue for 2021 was $2.29B, representing an increase of 7.89% compared to 2020.

What is Royalty Pharma’s quarterly revenue?

Royalty Pharma's quarterly revenue for Q3 2024 was $564.69M, a 5.10% increase from the previous quarter (Q2 2024), and a 5.29% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $537.27M, a -5.41% decrease from the previous quarter (Q1 2024), and a -0.17% decrease year-over-year (Q2 2023). RPRX's quarterly revenue for Q1 2024 was $567.98M, a -4.70% decrease from the previous quarter (Q4 2023), and a -16.96% decrease year-over-year (Q1 2023).

What is Royalty Pharma’s revenue growth rate?

Royalty Pharma's revenue growth rate for the last 3 years (2021-2023) was 2.84%, and for the last 5 years (2019-2023) was 29.78%.

What are Royalty Pharma’s revenue streams?

Royalty Pharma's revenue streams in c 23 are Intangible Royalty Assets, Financial Royalty Assets, and Royalty Income, Other. Intangible Royalty Assets generated $835K in revenue, accounting 0.04% of the company's total revenue, down -97.77% year-over-year. Financial Royalty Assets generated $2.2B in revenue, accounting 93.34% of the company's total revenue, up 3.42% year-over-year. Royalty Income, Other generated $155.96M in revenue, accounting 6.62% of the company's total revenue, up 108.97% year-over-year.

What is Royalty Pharma’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Royalty Pharma was Financial Royalty Assets. This segment made a revenue of $2.2B, representing 93.34% of the company's total revenue.